Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Surgical Management of Locoregional Melanoma

October 31st 2016

James Allison Says Rational Combinations Key to Immunotherapy Success in "Cold" Tumors

October 31st 2016

Immunotherapy has been a game changer in oncology, improving survival and providing long, durable responses in melanoma, lung, head and neck cancer, and others.

Active Surveillance a Valued Approach for Early Prostate Cancer

October 28th 2016

Before undergoing surgery, radiation therapy, or a systemic treatment, Clayton S. Lau, MD, advises that the active surveillance approach for some patients with early prostate cancer is likely a more effective approach—but they should be better educated on it.

Dr. Saenger on the Importance of Biomarkers When Administering Immunotherapy

October 27th 2016

Yvonne Saenger, MD, director of Melanoma Immunotherapy at Columbia University Medical Center, discusses the importance of developing accurate biomarkers when it comes to administering immunotherapy.

Immunotherapy Potentially Promising for Treatment of ATC

October 21st 2016

Given the poor prognoses often seen in patients with anaplastic thyroid cancer, researchers are seeking novel therapies that may hold more promise than surgery or radiation.

Dr. Rimm on Biomarker Testing in Lung Cancer

October 19th 2016

David L. Rimm, MD, PhD, professor of pathology and of medicine, director of pathology tissue services, director of translational pathology, Yale Cancer Center, discusses various options for biomarker testing in lung cancer.

Dr. Cohen on Biomarker Testing in Head and Neck Cancer

October 15th 2016

Ezra Cohen, MD, associate director, Moores Cancer Center, professor of Medicine, University of California, San Diego Health System, discusses biomarker testing in patients with head and neck cancer.

Niraparib Highly Effective as Maintenance Therapy for Recurrent Ovarian Cancer

October 8th 2016

Maintenance therapy with niraparib reduced the risk of progression or death by 73% compared with placebo for patients with germline BRCA-positive platinum-sensitive, recurrent ovarian cancer.

Targeted Treatments Still King in Kidney Cancer, Novel Combinations on the Horizon

October 4th 2016

In kidney cancer there are three “eras” in the history of treatment advances, said James Hsieh, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center.

Dr. Katz on Precision Medicine in Breast Cancer

October 4th 2016

Steven Katz, MD, professor, Internal Medicine, University of Michigan Health System, discusses the incorporation of precision medicine into the treatment paradigm of breast cancer.

Dr. Dadu on Current Treatment Approaches in Anaplastic Thyroid Cancer

September 30th 2016

Ramona Dadu, MD, assistant professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, discusses the current treatment approaches being evaluated for patients with anaplastic thyroid cancer.

Biology of Triple-Negative Breast Cancer Crucial for Most Effective Treatment

September 15th 2016

It is important to achieve a complete and thorough understanding of triple-negative breast cancer in order to most effectively treat patients.

Dr. O'Shaughnessy on Precision Medicine in Triple Negative Breast Cancer

September 14th 2016

Joyce O'Shaughnessy, MD, co-chair, breast cancer research, chair breast cancer at Baylor University Medical Center, discusses precision medicine in triple negative breast cancer.

Dr. Postow on the Current Treatment Landscape in Melanoma

September 8th 2016

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the current treatment landscape in melanoma.

Dr. Leslie M. Randall on Early BRCA Testing in Ovarian Cancer

September 2nd 2016

Dr. Hays on Targeting Mutations in Gynecologic Cancers

August 26th 2016

John Hays, MD, assistant professor of Internal Medicine, Ohio State University Comprehensive Cancer Center, discusses how researchers are actively exploring how to target rarer mutations in patients with a variety of gynecologic cancers.

Challenges With a Precision Medicine-Based Approach in Oncology

August 1st 2016

Holli Dilks, PhD, director, Personalized Medicine Operations, Sarah Cannon Research Institute, discusses the challenges associated with having a precision medicine-based approach in the field of oncology.

Impact of Precision Medicine in Refractory Malignancies

July 28th 2016

Maria Schwaederle, PharmD, Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California, San Diego, discusses results of a meta-analysis of 13,203 patients in phase I clinical trials.

Early Assessment of BRCA Status Key in Ovarian Cancer, Two Experts Agree

July 19th 2016

Robert Coleman, MD, and Leslie Randall, MD, provide further insight on the importance of BRCA testing.

Osimertinib Extends PFS in Phase III Study for T790M-Mutant NSCLC

July 18th 2016

The phase III AURA3 study has confirmed the benefits of osimertinib seen in earlier phase II studies for patients with EGFR T790M-mutant locally-advanced or metastatic non–small cell lung cancer following progression on a frontline EGFR TKI.